Aida Seitaliyeva

Dr. Aida Seitaliyeva

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2025 in Medicina
Verified
Journal Article
Open access
PDF file
ZDZaure Datkhayeva
Zaure Datkhayeva
AIAinur Iskakova
Ainur Iskakova
AМAлла Миреева
Aлла Миреева
ASAida Seitaliyeva
Aida Seitaliyeva
RSRaikhan Skakova
Raikhan Skakova
AAAkerke Amirkhanova
Akerke Amirkhanova
Endometriosis (EM) is a common estrogen-dependent chronic inflammatory disorder affecting reproductive-aged women, yet its pathogenesis remains incompletely understood. Recent evidence suggests that the gut microbiota significantly influence immune responses, estrogen metabolism, and systemic inflammation, potentially contributing to EM progression. This narrative review explores the relationship between the gut microbiota and EM, emphasizing microbial dysbiosis, inflammation, estrogen regulation, and potential microbiome-targeted therapies. Studies published within the last 30 years were included, focusing on the microbiota composition, immune modulation, estrogen metabolism, and therapeutic interventions in EM. The selection criteria prioritized peer-reviewed articles, clinical trials, meta-analyses, and narrative reviews investigating the gut microbiota’s role in EM pathophysiology and treatment. Microbial dysbiosis in EM is characterized by a reduced abundance of beneficial bacteria (Lactobacillus, Bifidobacterium, and Ruminococcaceae) and an increased prevalence of pro-inflammatory taxa (Escherichia/Shigella, Streptococcus, and Bacteroides). The gut microbiota modulate estrogen metabolism via the estrobolome, contributing to increased systemic estrogen levels and lesion proliferation. Additionally, lipopolysaccharides (LPS) from Gram-negative bacteria activate the TLR4/NF-κB signaling pathway, exacerbating inflammation and EM symptoms. The interaction between the gut microbiota, immune dysregulation, and estrogen metabolism suggests a critical role in EM pathogenesis. While microbiota-targeted interventions offer potential therapeutic benefits, further large-scale, multi-center studies are needed to validate microbial biomarkers and optimize microbiome-based therapies for EM. Integrating microbiome research with precision medicine may enhance the diagnostic accuracy and improve the EM treatment efficacy.

22 June 2022 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
DSDaniya Serdaliyeva
Daniya Serdaliyeva
TNTalgat Nurgozhin
Talgat Nurgozhin
ESElmira Satbayeva
Elmira Satbayeva
MKMalika Khayitova
Malika Khayitova
ASAida Seitaliyeva
Aida Seitaliyeva
LALarisa Ananyeva
Larisa Ananyeva
Imidazole derivatives are the perspective class of drugs with a broad spectrum of application in medicine. Imidazole is a nitrogen-containing heterocyclic ring; it has two equivalent forms; hydrogen atom may be located on any of two nitrogen atoms. Imidazole ring may interact with various cations and anions, as well as with biomolecules by different reactions; the presence of various groups in the nitrogenous heterocycle structure makes it possible to identify substances with a broad spectrum of pharmacological effects. They are very important for the production of new drugs and recently draw the special interest of scientists due to their properties in the chemistry and pharmacology. Introduction of highly active Imidazole has stimulated the significant achievements in the field of chemotherapeutic agents and plays the very important role in medicine. Therefore, the active search for highly active Imidazole compounds still continues. This article describes the antifungal and antibacterial effects identified in preclinical studies through a literature review. The purpose of this work is to review the principal effects of Imidazole published in the scientific literature in recent years.

28 May 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
AWA.O. Whaley
A.O. Whaley
DID.Y. Ivkin
D.Y. Ivkin
KZKarlygash Zhaparkulova
Karlygash Zhaparkulova
IOI.N. Olusheva
I.N. Olusheva
ESE.B. Serebryakov
E.B. Serebryakov
AWA.K. Whaley
A.K. Whaley

29 January 2017 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
Aurelija RadzevičienėAurelija Radzevičienė
Aurelija Radzevičienė
RARizvangul Ayupova
Rizvangul Ayupova
ESElmira Satbayeva
Elmira Satbayeva
ASAida Seitaliyeva
Aida Seitaliyeva
MAMarzhan Amirkulova
Marzhan Amirkulova
ESEdgaras Stankevičius
Edgaras Stankevičius
BACKGROUND:The aim of this study was to analyze the antifungal activity and the general toxicity of a new dental gel containing essential oil from the tree Abies sibirica L., which grows in the Republic of Kazakhstan. MATERIAL AND METHODS:The essenti...

15 January 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
GKGaukhar Koshkimbayeva
Gaukhar Koshkimbayeva
AAAkerke Amirkhanova
Akerke Amirkhanova
AOAiken Orazymbetova
Aiken Orazymbetova
ANAlma Nurakhova
Alma Nurakhova
AMAkmaral Maimakova
Akmaral Maimakova
SYSandugash Yerkenova
Sandugash Yerkenova
Background and objectives: Gynecologic cancers, including cervical, endometrial, and ovarian malignancies, remain among the leading causes of cancer-related illness and death in women worldwide. Despite progress in surgery and chemotherapy, resistance to conventional cytotoxic drugs continues to limit durable outcomes. The introduction of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs) has created new therapeutic opportunities by improving survival and overcoming resistance mechanisms. This review summarizes the latest clinical evidence on immunotherapy and ADC-based regimens, emphasizing their integration into current treatment strategies and the expanding roles of genomic profiling and artificial intelligence (AI) in personalized therapy. Materials and methods: Recent findings from major clinical trials such as RUBY, NRG-GY018, DUO-O, SORAYA, and DESTINY-PanTumor02 were evaluated along with updated FDA and NCCN recommendations. The analysis focuses on treatments that have demonstrated clinical benefit in advanced or recurrent disease, including pembrolizumab, dostarlimab, tisotumab vedotin, and mirvetuximab soravtansine. Combination strategies incorporating PARP inhibitors, antiangiogenic agents, and immune checkpoint blockade were also reviewed. Results: Checkpoint inhibitors have achieved meaningful clinical benefits in patients with advanced or recurrent endometrial and cervical cancers, particularly in those with mismatch repair deficiency or PD-L1 expression. ADCs directed against tissue factor (TF) and folate receptor alpha have shown effectiveness in platinum-resistant cervical and ovarian cancers. Combination regimens that include ICIs, PARP inhibitors, or antiangiogenic therapy are yielding encouraging results in both first-line and maintenance settings. Advances in molecular profiling and biomarker-based patient selection, supported by AI applications, are further improving treatment precision in gynecologic oncology. Conclusions: Immunotherapy and ADCs represent major advances in the treatment of gynecologic cancers. Their growing integration into clinical practice has reshaped therapeutic approaches, while ongoing research continues to refine optimal combinations, address resistance, and enhance biomarker-guided selection. Future developments are expected to unite immunologic, genomic, and computational strategies to achieve personalized and durable outcomes for patients with gynecologic malignancies.

15 April 2025 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Open access
PDF file
ZDZaure Dushimova
Zaure Dushimova
MAM.O. Alhassan
M.O. Alhassan
ARAsylkhan Rakhymzhan
Asylkhan Rakhymzhan
AAArailym Aralbaeva
Arailym Aralbaeva
ASAida Seitaliyeva
Aida Seitaliyeva
Relevance: Integrating molecular biomarkers with rigorous quality control (QC) measures in laboratory settings is essential for enhancing early detection strategies and prognostic evaluation in cancer patients. Precision and QC in laboratory diagnostics of oncological diseases have become particularly significant in the widespread implementation of targeted and personalized therapy. The study aimed to review publications evaluating quality control in biomarker identification within molecular genetics laboratories, using ovarian cancer diagnostics as a case study.Methods: This systematic literature review conducted in the framework of this study revealed 220 records, leading to 165 unique publications, of which 24 full-text articles were included in this review. The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (PRISMA 2020) guidelines. Results: All analyzed sources showed that Implementing QC, including calibration, internal controls, and proficiency testing provided by the College of American Pathologists (CAP), significantly reduces errors despite ongoing funding constraints. The European Molecular Quality Network (EMQN) and CAP jointly offer proficiency testing programs to evaluate laboratory performance globally, ensuring consistency and reliability in testing outcomes. Conclusion: Ensuring the accuracy and reliability of molecular diagnostic tests is critical in clinical settings, particularly for conditions such as ovarian cancer, where precise genetic analysis informs both diagnosis and treatment. Further advancements in early detection and personalized treatment can be achieved by integrating emerging technological innovations within robust QC framework, ultimately improving patient outcomes. Consequently, the establishment of standardized guidelines and standard operating procedures for molecular genetic testing, with a specific focus on the molecular genetic diagnosis of ovarian cancer, is imperative.